{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:25:25Z","timestamp":1792783525345,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"SBI Pharmaceuticals","id":[{"id":"https:\/\/ror.org\/028mhrr87","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In Japan, the authorized period (2\u20134 h) between oral administration of 5-aminolevulinic acid hydrochloride (5-ALA) and transurethral resection for non-muscle invasive bladder cancer (NMIBC) may restrict photodynamic diagnosis (PDD) usage. Therefore, this prospective, single-arm, phase III study aimed to evaluate the diagnostic accuracy and safety of PDD at an extended administration period (4\u20138\u00a0h).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From January 2022 to May 2023, 161 patients with NMIBC were enrolled from eight hospitals. The primary endpoint was the blue light (BL) sensitivity of pathologically positive biopsies. The secondary endpoints were a comparison of the specificity and positive and negative prediction rates under BL and white light (WL) conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1242 specimens comprising 337 histological NMIBC specimens were analyzed. BL-sensitivity was 95.3%. Its lower limit of 95% confidence interval (92.4\u201397.3%) exceeded the threshold (70%) of non-inferiority to authorized usage. Sensitivity and specificity were significantly higher and lower for BL than those for WL (95.3% vs. 61.1%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001; 52.7% vs. 95.2%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), respectively. The positive and negative predictive rates were significantly lower and higher for BL than those for WL (42.9% vs. 82.7%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001; 96.8% vs. 86.8%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), respectively. Of the 145 patients receiving 5-ALA, 136 (93.8%) and 75 (51.7%) experienced 377 adverse events and 95 adverse reactions, respectively, most of which were grade 1 or 2.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>For extended period, the efficacy of PDD for NMIBC was similar to that of authorized period, in terms of higher sensitivity and lower specificity compared with WL, and the safety was acceptable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-024-02638-5","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T13:01:33Z","timestamp":1728306093000},"page":"110-120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effect of extending the period from oral administration of 5-aminolevulinic acid hydrochloride to photodynamic diagnosis during transurethral resection for non-muscle invasive bladder cancer on diagnostic accuracy and safety: a single-arm multicenter phase III trial"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3243-499X","authenticated-orcid":false,"given":"Rikiya","family":"Taoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makito","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent","family":"Kanao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Komai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikio","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyonori","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyohide","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Oya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,7]]},"reference":[{"key":"2638_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263","journal-title":"CA Cancer J Clin"},{"key":"2638_CR2","volume-title":"The Bethesda handbook of clinical oncology","author":"J Abraham","year":"2019","unstructured":"Abraham J, Gulley JL (2019) The Bethesda handbook of clinical oncology, 5th edn. Wolters Kluwer Health, Philadelphia","edition":"5"},{"key":"2638_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O et al (2022) European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 81:75\u201394","journal-title":"Eur Urol"},{"key":"2638_CR4","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","volume":"196","author":"SS Chang","year":"2016","unstructured":"Chang SS, Boorjian SA, Chou R et al (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline. J Urol 196:1021\u20131029","journal-title":"J Urol"},{"key":"2638_CR5","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/iju.14281","volume":"27","author":"H Matsumoto","year":"2020","unstructured":"Matsumoto H, Shiraishi K, Azuma H et al (2020) Clinical practice guidelines for bladder cancer 2019 update by the Japanese urological association: Summary of the revision. Int J Urol 27:702\u2013709","journal-title":"Int J Urol"},{"key":"2638_CR6","unstructured":"Cancer Stat Facts, Bladder cancer. National Institutes of Health \u2013 National Cancer Institute: Surveillance, Epidemiology and End Results Program. https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html. Accessed Jan 21, 2024."},{"key":"2638_CR7","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.urology.2006.12.023","volume":"69","author":"S Denzinger","year":"2007","unstructured":"Denzinger S, Burger M, Walter B et al (2007) Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology 69:675\u2013679","journal-title":"Urology"},{"key":"2638_CR8","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1002\/cncr.26378","volume":"118","author":"K Inoue","year":"2012","unstructured":"Inoue K, Fukuhara H, Shimamoto T et al (2012) Comparison between intravesical and oral administration of 5-aminolevulinic acid in the clinical benefit of photodynamic diagnosis for nonmuscle invasive bladder cancer. Cancer 118:1062\u20131074","journal-title":"Cancer"},{"key":"2638_CR9","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/iju.13718","volume":"25","author":"Y Nakai","year":"2018","unstructured":"Nakai Y, Inoue K, Tsuzuki T et al (2018) Oral 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: a multicenter phase III study. Int J Urol 25:723\u2013729","journal-title":"Int J Urol"},{"key":"2638_CR10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.pdpdt.2015.03.008","volume":"12","author":"K Inoue","year":"2015","unstructured":"Inoue K, Anai S, Fujimoto K et al (2015) Oral 5-aminolevulinic acid mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: a randomized, double-blind, multicentre phase II\/III study. Photodiagnosis Photodyn Ther 12:193\u2013200","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"2638_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3390\/diagnostics11020185","volume":"11","author":"M Miyake","year":"2021","unstructured":"Miyake M, Nishimura N, Nakai Y et al (2021) Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases the risk of repeated recurrence in non-muscle-invasive bladder cancer: a cumulative incidence analysis by the person-time method. Diagnostics (Basel) 11:185","journal-title":"Diagnostics (Basel)"},{"key":"2638_CR12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/bco2.215","volume":"4","author":"M Miyake","year":"2023","unstructured":"Miyake M, Nishimura N, Nakahama T et al (2023) Additional oncological benefit of photodynamic diagnosis with blue light cystoscopy in transurethral resection for primary non-muscle-invasive bladder cancer: a comparative study from experienced institutes. BJUI Compass 4:305\u2013313","journal-title":"BJUI Compass"},{"key":"2638_CR13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/jjco\/hyac203","volume":"53","author":"N Nishimura","year":"2023","unstructured":"Nishimura N, Miyake M, Miyamoto T et al (2023) The Japanese health care system-based cost-effectiveness of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer. Jpn J Clin Oncol 53:343\u2013348","journal-title":"Jpn J Clin Oncol"},{"key":"2638_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2020.101999","volume":"32","author":"S Yamamoto","year":"2020","unstructured":"Yamamoto S, Fukuhara H, Karashima T et al (2020) Real-world experience with 5-aminolevulinic acid for the photodynamic diagnosis of bladder cancer: diagnostic accuracy and safety. Photodiagnosis Photodyn Ther 32:101999","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"2638_CR15","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.eururo.2018.02.014","volume":"73","author":"MGK Cumberbatch","year":"2018","unstructured":"Cumberbatch MGK, Foerster B, Catto JWF et al (2018) Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review. Eur Urol 73:925\u2013933","journal-title":"Eur Urol"},{"key":"2638_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2022.102757","volume":"38","author":"H Fukuhara","year":"2022","unstructured":"Fukuhara H, Yamamoto S, Lai HW et al (2022) Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (2nd report): reduced bladder recurrence after PDD-TURBT. Photodiagnosis Photodyn Ther 38:102757","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"2638_CR17","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000195537","volume":"76","author":"H Matsuyama","year":"2009","unstructured":"Matsuyama H, Yamamoto Y, Nagao K et al (2009) Cytogenetic analysis of false-positive mucosa by photodynamic diagnosis using 5-aminolevulinic acid\u2014possible existence of premalignant genomic alterations examined by in vitro experiment. Oncology 76:118\u2013125","journal-title":"Oncology"},{"key":"2638_CR18","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.euf.2016.12.011","volume":"4","author":"A Naselli","year":"2018","unstructured":"Naselli A, Hurle R, Paparella S et al (2018) Role of restaging transurethral resection for t1 non-muscle invasive bladder cancer: a systematic review and meta-analysis. Eur Urol Focus 4:558\u2013567","journal-title":"Eur Urol Focus"},{"key":"2638_CR19","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/bju.15723","volume":"130","author":"P Maisch","year":"2022","unstructured":"Maisch P, Koziarz A, Vajgrt J et al (2022) Blue vs white light for transurethral resection of non-muscle-invasive bladder cancer: an abridged cochrane review. BJU Int 130:730\u2013740","journal-title":"BJU Int"},{"key":"2638_CR20","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1111\/iju.14099","volume":"26","author":"T Nohara","year":"2019","unstructured":"Nohara T, Kato Y, Nakano T et al (2019) Intraoperative hypotension caused by oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer. Int J Urol 26:1064\u20131068","journal-title":"Int J Urol"},{"key":"2638_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40981-020-00340-9","volume":"6","author":"T Yatabe","year":"2020","unstructured":"Yatabe T, Karashima T, Kume M et al (2020) Identification of risk factors for post-induction hypotension in patients receiving 5-aminolevulinic acid: a single-center retrospective study. JA Clin Rep 6:35","journal-title":"JA Clin Rep"},{"key":"2638_CR22","first-page":"374","volume":"4","author":"T Shiratori","year":"2021","unstructured":"Shiratori T, Hotta K, Satoh M et al (2021) Differences in 5-aminolevulinic acid-induced hemodynamic changes between patients undergoing neurosurgery and urological surgery. JMA J 4:374\u2013386","journal-title":"JMA J"}],"updated-by":[{"DOI":"10.1007\/s10147-024-02654-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000}}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02638-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02638-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02638-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T13:02:34Z","timestamp":1735995754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02638-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,7]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["2638"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02638-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,7]]},"assertion":[{"value":"21 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article has been changed to open access retrospectively.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10147-024-02654-5","URL":"https:\/\/doi.org\/10.1007\/s10147-024-02654-5","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflict of interest except that K. I. and H. F. received research funding from SBI outside this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}